Acne Treatment Using Delayed Light Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ALA-based photodynamic therapy (PDT) methods for treating acne are not effective due to lack of specificity for acne lesions and diminished effectiveness over time, with previous studies suggesting that ALA-induced protoporphyrin IX is largely dissipated within 12 hours, leading to inconclusive results.
Innovation Solution
Delaying light exposure after applying aminolevulinic acid hydrochloride to the skin by at least 12 hours, and potentially up to 36 hours, allows for optimal localization of protoporphyrin IX in acne lesions, enhancing the specificity and effectiveness of ALA-based PDT for acne treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If light exposure is delayed beyond 12 hours after ALA application, then specificity for acne lesions is improved, but treatment time is increased
Solution Approach 1:
The patent applies preliminary action by allowing protoporphyrin IX to accumulate and localize specifically in acne lesions during the 12-36 hour delay period before light exposure. This pre-positioning of the photosensitizing agent ensures that when light is applied, the energy is concentrated precisely where needed (in acne lesions) rather than being distributed throughout the skin, thereby achieving high specificity without requiring complex targeting mechanisms.
2Reliability
If light exposure is delayed up to 36 hours after ALA application, then effectiveness of treatment is improved, but patient compliance becomes more difficult
Solution Approach 1:
The patent applies parameter changes by optimizing the time parameter between ALA application and light exposure. By identifying that the optimal window extends to 12-36 hours (contrary to the conventional 1-12 hour window), the patent changes the temporal parameter of the treatment protocol to maximize protoporphyrin IX localization and treatment effectiveness, thereby resolving the contradiction between achieving reliable results and maintaining ease of operation.
3Productivity
If conventional ALA-based PDT is used with light exposure within 1-12 hours, then treatment time is reduced, but specificity for acne lesions is insufficient
Solution Approach 1:
The patent applies dynamics by treating the timing of light exposure as a dynamic variable rather than a fixed parameter. By establishing that the optimal timing window is 12-36 hours after ALA application (rather than the static conventional 1-12 hour window), the patent dynamically optimizes the treatment protocol to allow protoporphyrin IX to naturally accumulate and localize in acne lesions over time, thereby achieving both high specificity and maintained treatment efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in a significantly more effective treatment for acne, with improved specificity for acne lesions and increased duration of protoporphyrin IX persistence, leading to a substantial reduction in acne lesion severity and number over time.
Implementation Method 1
The light is used to cause a reaction (such as photoexcitation) in either the phototherapeutic agent, or in a metabolite of the phototherapeutic agent
Implementation Method 2
ALA is a precursor to a naturally occurring molecule - protoporphyrin IX. Exposing skin to light activates protoporphyrin IX in the skin
Data Source
AI summary
This application is directed to a method of treating a patient with acne by applying a photodynamic agent to skin having acne lesions, waiting at least 12 hours, and then exposing the skin to which the photodynamic agent has been applied to light that causes an activation reaction.